{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:18:10Z","timestamp":1780377490102,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals International AG Singapore Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed\/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016\u20132023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0\u00a0years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1\u00a0months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7\u00a0months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (\u226565 and\/or \u226570\u00a0years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade\u2009\u2265\u20093 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.<\/jats:p>","DOI":"10.1007\/s12185-025-03927-z","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:54:47Z","timestamp":1742464487000},"page":"670-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"121","author":[{"given":"Soo Chin","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Wilfred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azlan","family":"Husin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SFadilah","family":"Abdul Wahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-won","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suporn","family":"Chuncharunee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"9","key":"3927_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3927_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138.","journal-title":"Leukemia"},{"issue":"17","key":"3927_CR3","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"3927_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12185-022-03479-6","volume":"117","author":"JH Lee","year":"2023","unstructured":"Lee JH, Kim SH, Kim HR, Min CK, Lee JJ, Shin HJ, et al. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and\/or refractory multiple myeloma. Int J Hematol. 2023;117(2):225\u201335.","journal-title":"Int J Hematol"},{"issue":"3","key":"3927_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M. Ixazomib: first global approval. Drugs. 2016;76(3):405\u201311.","journal-title":"Drugs"},{"issue":"22","key":"3927_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3927_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","volume":"10","author":"J Hou","year":"2017","unstructured":"Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017;10(1):137.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3927_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00277-023-05428-7","volume":"103","author":"Y Horigome","year":"2024","unstructured":"Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, et al. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in Japan. Ann Hematol. 2024;103(2):475\u201388.","journal-title":"Ann Hematol"},{"issue":"1","key":"3927_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8\u201317.e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"3927_CR10","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2019-125749","volume":"134","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee HC, Abonour R, Rifkin RM, Terpos E, Leleu X, et al. Real-world (RW) multiple myeloma (MM) patients (pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3000 pts from the Insight MM global, prospective, observational study. Blood. 2019;134(Supplement_1):1887\u201397.","journal-title":"Blood"},{"issue":"19","key":"3927_CR11","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/fon-2020-1225","volume":"17","author":"R H\u00e1jek","year":"2021","unstructured":"H\u00e1jek R, Mina\u0159\u00edk J, Straub J, Pour L, Jungova A, Berdeja JG, et al. Ixazomib\u2013lenalidomide\u2013dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma. Future Oncol. 2021;17(19):2499\u2013512.","journal-title":"Future Oncol"},{"issue":"20","key":"3927_CR12","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.3390\/cancers14205165","volume":"14","author":"J Minarik","year":"2022","unstructured":"Minarik J, Radocha J, Jungova A, Straub J, Jelinek T, Pika T, et al. Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy. Cancers. 2022;14(20):5165.","journal-title":"Cancers"},{"issue":"5","key":"3927_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-020-03981-z","volume":"99","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E, et al. Real-world effectiveness and safety of ixazomib\u2013lenalidomide\u2013dexamethasone in relapsed\/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049\u201361.","journal-title":"Ann Hematol"},{"issue":"1","key":"3927_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12885-020-07732-1","volume":"21","author":"J Minarik","year":"2021","unstructured":"Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21(1):73.","journal-title":"BMC Cancer"},{"issue":"12","key":"3927_CR15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3927_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2217\/fon-2023-0604","volume":"20","author":"X Leleu","year":"2024","unstructured":"Leleu X, Lee HC, Zonder JA, Macro M, Ramasamy K, Hulin C, et al. INSURE: a pooled analysis of ixazomib\u2013lenalidomide\u2013dexamethasone for relapsed\/refractory myeloma in routine practice. Future Oncol. 2024;20(14):935\u201350.","journal-title":"Future Oncol"},{"issue":"2","key":"3927_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.14214","volume":"113","author":"HC Lee","year":"2024","unstructured":"Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, et al. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib\u2013lenalidomide\u2013dexamethasone for relapsed\/refractory multiple myeloma: a pooled analysis from the INSURE study. Eur J Haematol. 2024;113(2):190\u2013200.","journal-title":"Eur J Haematol"},{"issue":"8","key":"3927_CR18","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00277-023-05278-3","volume":"102","author":"M Macro","year":"2023","unstructured":"Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, et al. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: the REMIX study. Ann Hematol. 2023;102(8):2137\u201351.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"3927_CR19","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1182\/blood-2022-163071","volume":"140","author":"RE Birhiray","year":"2022","unstructured":"Birhiray RE, Rifkin RM, Yasenchak CA, Fields-Meehan J, Lyons RM, Ratnasabapathy R, et al. In-class transition (ICT) from parenteral bortezomib to oral ixazomib therapy in newly diagnosed multiple myeloma (NDMM) patients from the community-based US MM-6 study: subgroup analyses of the fully accrued dataset in patients aged <75 and \u226575 years. Blood. 2022;140(Supplement 1):7322\u20133.","journal-title":"Blood"},{"issue":"7","key":"3927_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7071","volume":"13","author":"A Furlan","year":"2024","unstructured":"Furlan A, Cea M, Zambello R, Pavan L, Galli M, Clissa C, et al. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: the northern Italy experience. Cancer Med. 2024;13(7): e7071.","journal-title":"Cancer Med"},{"issue":"6","key":"3927_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00277-020-03985-9","volume":"99","author":"YC Cohen","year":"2020","unstructured":"Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, et al. Ixazomib-based regimens for relapsed\/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Ann Hematol. 2020;99(6):1273\u201381.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"3927_CR22","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1182\/blood-2022-156320","volume":"140","author":"L Sanchez","year":"2022","unstructured":"Sanchez L, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Huang F, et al. Comparative effectiveness of lenalidomide\/dexamethasone-based triplet regimens for treatment of relapsed and\/or refractory multiple myeloma in subgroups defined by cytogenetic risk. Blood. 2022;140(Supplement 1):4308\u20139.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03927-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:48:37Z","timestamp":1745318917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03927-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3927"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03927-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hye-won Heo was an employee of Takeda Pharmaceuticals Korea Co., Ltd. Ji Hyun Lee has received honoraria\/research funding from Takeda, Amgen, Janssen, Celgene-BMS, Sanofi and JW Pharmaceutical, and was a consultant for Takeda, Amgen and Janssen. Youngil Koh holds a leadership position at Genome Opinion, holds stock\/options in Genome Opinion, Curocell, Proteina and Tomocube, and has received research funding from Sanofi-Genzyme and Roche. Soo Chin Ng has received consultation fees\/honorarium for participation in advisory boards from Roche, AstraZeneca, Novartis and BeiGene. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}